Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +37.72%
#2 Versatize Coin Versatize Coin +32.51%
#3 Siren Siren +30.99%
#4 Purr Purr +28.11%
#5 Official Trump Official Trump +20.50%
#6 OriginTrail OriginTrail +17.22%
#7 Prom Prom +17.05%
#8 ApeX ApeX +16.64%
#9 UnifAI Network UnifAI Network +15.84%
#10 Pendle Pendle +14.37%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Classement en actions #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Prix de l'action
$50.82
Dernière synchronisation: 2026-08-11
Capitalisation boursière
$102.09M
Changement (1 jour)
1.90%
Changement (1 an)
-
Pays
US
Échange Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Catégorie

Healthcare
Ratio P/B pour Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Hemab Therapeutics Holdings, Inc. Common Stock, le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Hemab Therapeutics Holdings, Inc. Common Stock de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH